Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

S1 Versus Capecitabine in the First Line Treatment of Metastatic Colorectal Cancer Patients, the SALTO Randomised Phase III Study of the Dutch Colorectal Cancer Group. A Safety Evaluation of Oral Fluoropyrimidines

NCT01918852 is registered in ClinicalTrials.gov with Dutch Colorectal Cancer Group as lead sponsor.

NCT NCT01918852
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01918852 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
S1 Versus Capecitabine in the First Line Treatment of Metastatic Colorectal Cancer Patients, the SALTO Randomised Phase III Study of the Dutch Colorectal Cancer Group. A Safety Evaluation of Oral Fluoropyrimidines
Lead sponsor
Dutch Colorectal Cancer Group
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2013
Completion date
March 31, 2018
Enrollment
161 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, metastases